UNT HEALTH SCIENCE CENTER

Enhanced chemotherapy against glial cancer cells

Learn more!
Robert McClain, PhD
Associate Vice President
robert.mcclain@unthsc.edu
817-735-2618

Technology Case
2010-17

Our Inventor
Meharvan Singh, PhD
meharvan.singh@unthsc.edu

Patent Status
- US Patent pending
- Published as US 20120040914

Discovery

- The presence of a novel receptor target for androgens, when activated, renders the tumor cell more vulnerable to chemotherapy while simultaneously affording protection of neuronal cells.

Features

- In vitro studies show that receptor activation enhances cytotoxicity of Temozolamide in gliobastoma cells.
- Receptor activation protected hippocampal cells from glutamate-induced cytotoxicity.

Benefits

- Fewer side effects related to the toxic consequences of the chemotherapy
- Less damage to healthy brain tissue proximate to glial tumors

Opportunities

- Potential means of treating glial cancers that have not historically responded well to existing chemotherapeutics
- With existing technologies, survival rate of patients with glioblastoma is less than 5% at five years.

3500 Camp Bowie Blvd
Fort Worth, TX 76107
Phone: 817-735-5147
FAX: 817-735-5485
techtransfer@unthsc.edu